NeuroPace Inc (NASDAQ: NPCE)

NeuroPace, Inc. is a medical device company focused on developing and commercializing responsive neurostimulation therapies for patients with drug resistant epilepsy. The company’s flagship product, the RNS System, is a brain responsive neurostimulation device that continuously monitors intracranial electroencephalogram activity, detects patient specific abnormal patterns, and delivers targeted electrical stimulation to prevent seizures. NeuroPace’s RNS System is the first and only FDA approved closed loop system that both provides therapy and records brain data for clinician review. As of December 31, 2024, more than 6,000 patients had received the RNS System, and the company estimates that approximately 575,000 adults in the United States suffer from drug resistant focal epilepsy, representing a total addressable market of about $27 billion. The company operates within the neurological devices sector of the healthcare industry, aiming to reduce seizure frequency and improve quality of life for a patient population that has limited response to antiepileptic drugs.

NeuroPace generates revenue principally from the sale of its RNS System neurostimulator, cortical and depth leads, and related accessories to hospitals and epilepsy centers that perform implant procedures. In addition to the initial system sale, the company earns recurring revenue from the replacement neurostimulator, which is required approximately every eleven years when the device’s battery reaches end of life. NeuroPace also benefits from the reimbursement environment surrounding its product, as hospitals and physicians receive payment for implantation, intraoperative programming, and follow up services such as periodic in person or remote review of the recorded brain activity data. The company’s sales are conducted primarily through a direct sales force in the United States, targeting epileptologists who prescribe the system and neurosurgeons who implant it, with substantially all revenue derived from domestic markets.

NeuroPace occupies a differentiated niche in the epilepsy neuromodulation market, where its RNS System is the only FDA approved device that combines responsive stimulation with continuous intracranial electroencephalogram monitoring and data storage. The principal competitors in this space are LivaNova plc, which markets the vagus nerve stimulation system, and Medtronic plc, which markets the deep brain stimulation system for epilepsy. Unlike those continuous stimulation technologies, the RNS System delivers therapy only when abnormal brain activity is detected, resulting in an average of about three minutes of stimulation per day and a lower incidence of stimulation related side effects such as memory impairment or mood changes. NeuroPace’s competitive advantage is further reinforced by its proprietary data platform, which aggregates more than 19,000,000 intracranial electroencephalogram records from over 6,000 implanted patients and enables clinicians to optimize therapy settings over time, thereby improving clinical outcomes. The company also benefits from established reimbursement for implantation, programming, and data review services, a feature not available for competing neuromodulation devices.

NeuroPace’s customers consist of hospitals and specialized epilepsy centers that have the capability to perform intracranial implantation of the neurostimulator, particularly the approximately 200 Level 4 comprehensive epilepsy centers in the United States. Within these centers, epileptologists serve as the prescribing physicians who identify appropriate patients and determine therapy parameters, while neurosurgeons carry out the surgical implantation of the leads and neurostimulator. The company also works with a growing network of epileptologists and functional neurosurgeons practicing outside of Level 4 centers following the 2023 PMA supplement approval that expanded prescribing rights to about 1,800 additional clinicians. Ultimately, the end users of the technology are patients diagnosed with drug resistant focal epilepsy who receive the implanted system and benefit from ongoing seizure reduction and improved quality of life.